they are starting again with TGA because they feel it should be registered in OSLs home country.
TGA can be a great preparatory and (often) bellweather process to preceed FDA submission, but it costs time, focus and $$. Registering in any jurisdiction should have a robust business case. 'Feeling' a product should be registered in your 'home country' is a poor justification for the use of sh funds, imo.
Ann: OncoSil onboards first patient in PANCOSIL Clinical Trial, page-19
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
-0.002(15.4%) |
Mkt cap ! $41.62M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $368.9K | 36.70M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2295654 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 6892565 | 14 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| OSL (ASX) Chart |